U.S. Oncologists See Promise In Cell And Gene Therapy, But Barriers Loom

A 2024 survey of U.S. oncologists reveals that while 99% agree that CGTs are among the most important medical innovations of our time, significant barriers to patient access persist. Insurance coverage and out-of-pocket costs are cited as the most common reasons why patients often receive other treatments instead of CGTs. Additionally, oncologists express concerns about the safety and side effect profiles of CGTs.

This lack of accessibility is a significant concern, as 94% of oncologists believe that CGTs have the potential to dramatically improve patients' quality of life. To learn more about the challenges and opportunities facing CGTs, access the infographic for additional insights.